AAAAAA
Results:
1-12
|
Results: 12
Authors:
REIGNER B
VERWEIJ J
DIRIX L
CASSIDY J
TWELVES C
ALLMAN D
WEIDEKAMM E
ROOS B
BANKEN L
UTOH M
OSTERWALDER B
Citation: B. Reigner et al., EFFECT OF FOOD ON THE PHARMACOKINETICS OF CAPECITABINE AND ITS METABOLITES FOLLOWING ORAL-ADMINISTRATION IN CANCER-PATIENTS, Clinical cancer research, 4(4), 1998, pp. 941-948
Authors:
REIGNER B
VERWEIJ J
DIRIX L
CASSIDY J
TWELVES C
ALLMAN D
WEIDEKAMM E
ROOS B
BANKEN L
UTOH M
OSTERWALDER B
Citation: B. Reigner et al., EFFECT OF FOOD ON THE PHARMACOKINETICS OF CAPECITABINE AND ITS METABOLITES FOLLOWING ORAL-ADMINISTRATION IN CANCER-PATIENTS, Clinical cancer research, 4(4), 1998, pp. 941-948
Authors:
PROPPER D
MCDONALD A
THAVASU P
BALKWILL F
CAPONIGRO F
YAP A
CHAMPAIN K
CSERMAK K
TALBOT D
KAYE S
HARRIS AL
TWELVES C
Citation: D. Propper et al., PHASE-I STUDY OF THE PROTEIN-KINASE-C INHIBITOR CGP-41251 - TOLERABILITY AND EFFECTS ON SIGNAL-TRANSDUCTION EX-VIVO, Annals of oncology, 9, 1998, pp. 428-428
Authors:
DEBONO JS
PROPPER D
ELLARD S
STEINER J
BEVAN P
DOBBS N
FLANAGAN E
GANESAN TS
TALBOT DC
CAMPBELL S
TWELVES C
HARRIS A
Citation: Js. Debono et al., A PHASE-I STUDY OF XR5000 (DACA) BY 120 HOUR INTRAVENOUS-INFUSION, Annals of oncology, 9, 1998, pp. 449-449
Authors:
BOWMAN A
TWELVES C
HOEKMAN K
SIMPSON A
SMYTH J
VERMORKEN J
HOPPENER F
BEIJNEN J
VEGA E
JIMENO J
HANAUSKE AR
Citation: A. Bowman et al., PHASE-I CLINICAL AND PHARMACOKINETIC (PK) STUDY OF ECTEINASCIDIN-743 (ET-743) GIVEN AS A ONE-HOUR INFUSION EVERY 21 DAYS, Annals of oncology, 9, 1998, pp. 452-452
Authors:
HILLEBRAND MJX
JIMENO J
CVITKOVIC E
HOEKMAN K
HOPPENER F
TWELVES C
VILLALONA M
ROSING H
BEIJNEN JH
Citation: Mjx. Hillebrand et al., PHARMACOKINETICS OF ECTEINASCIDIN-743 (ET-743) IN 3 PHASE-I STUDIES, Annals of oncology, 9, 1998, pp. 455-455
Authors:
MACKEAN M
PLANTING A
TWELVES C
SCHELLENS J
ALLMAN D
OSTERWALDER B
REIGNER B
GRIFFIN T
KAYE S
VERWEIJ J
Citation: M. Mackean et al., PHASE-I AND PHARMACOLOGICAL STUDY OF INTERMITTENT TWICE-DAILY ORAL-THERAPY WITH CAPECITABINE IN PATIENTS WITH ADVANCED AND OR METASTATIC CANCER/, Journal of clinical oncology, 16(9), 1998, pp. 2977-2985
Authors:
DEBONO J
BLEEHAN N
SECHER D
BEALE P
MOORE S
SLUDDEN J
DENNIS I
JUDSON I
TWELVES C
Citation: J. Debono et al., A PHASE-1 STUDY OF XR5000 BY 3HR IV INFUSION, British Journal of Cancer, 78, 1998, pp. 13-13
Authors:
PAZARES L
KUNKA R
DEMARIA D
CASSIDY J
ALDEN M
BERANEK P
KAYE S
LITTLEFIELD D
REILLY D
DEPEE S
WISSEL P
TWELVES C
ODWYER P
Citation: L. Pazares et al., A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE NEW TOPOISOMERASEINHIBITOR GI147211 GIVEN AS A 72-H CONTINUOUS-INFUSION, British Journal of Cancer, 78(10), 1998, pp. 1329-1336
Authors:
VASEY PA
PRONK L
TWELVES C
SPARREBOOM A
WILSON P
GORDON RJ
OSTERWALDER B
VERWEIJ J
Citation: Pa. Vasey et al., PHASE-I AND PHARMACOKINETIC STUDY OF XELODA(TM) (CAPECITABINE) IN COMBINATION WITH DOCETAXEL, European journal of cancer, 33, 1997, pp. 1113-1113
Authors:
TWELVES C
HARNETT A
Citation: C. Twelves et A. Harnett, ADVERTISEMENT FOR TOREMIFENE - PLAYING ON WOMENS FEARS IS UNETHICAL, BMJ. British medical journal, 313(7062), 1996, pp. 944-945
Authors:
PAZARES L
DOBBS N
TWELVES C
Citation: L. Pazares et al., DOXORUBICIN-INDUCED CARDIOTOXICITY, The New England journal of medicine, 333(20), 1995, pp. 1360-1360
Risultati:
1-12
|